Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Randomized, Placebo-controlled, Dose-escalation Study to Evaluate the Safety of MEDI4212 in Subjects With IgE >= 30 IU/mL

NCT01544348 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT01544348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01544348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Randomized, Placebo-controlled, Dose-escalation Study to Evaluate the Safety of MEDI4212 in Subjects With IgE >= 30 IU/mL
Lead sponsor
MedImmune LLC
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2012
Completion date
June 30, 2013
Enrollment
295 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

allergic asthma, allergic rhinitis, atopic dermatitis, healthy volunteers